The REMS Report Card: FDA Using New Tools For One-Third Of New Drugs In First Six Months

FDA has used its new authority to impose a Risk Evaluation and Mitigation Strategy on one-third of all new molecular entities approved since the REMS provisions of the FDA Amendments Act took effect at the end of March